NAMPT and neoplasm: Because problems related to targeting and dosage toxicity limit the clinical usage of NAMPT inhibitors, such as thrombocytopenia and gastrointestinal effects, targeted delivery to tumor tissues via the ADC pathway may significantly improve the therapeutic index.